309 related articles for article (PubMed ID: 10852275)
1. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.
Chevalet P; Barrier JH; Pottier P; Magadur-Joly G; Pottier MA; Hamidou M; Planchon B; El Kouri D; Connan L; Dupond JL; De Wazieres B; Dien G; Duhamel E; Grosbois B; Jego P; Le Strat A; Capdeville J; Letellier P; Agron L
J Rheumatol; 2000 Jun; 27(6):1484-91. PubMed ID: 10852275
[TBL] [Abstract][Full Text] [Related]
2. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
3. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
Martínez-Taboada VM; Rodríguez-Valverde V; Carreño L; López-Longo J; Figueroa M; Belzunegui J; Mola EM; Bonilla G
Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
[TBL] [Abstract][Full Text] [Related]
4. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
[TBL] [Abstract][Full Text] [Related]
5. [Bolus of methylprednisolone and Horton's disease/rhizomelic pseudo-polyarthritis. Preliminary results of a pilot study of treating the bolus with low doses of corticoids].
Juchet H; Arlet P; Ollier S; Montané de la Roque P; Le Tallec Y
Ann Med Interne (Paris); 1992; 143(2):85-8. PubMed ID: 1530225
[TBL] [Abstract][Full Text] [Related]
6. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
[TBL] [Abstract][Full Text] [Related]
7. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.
González-Gay MA; Blanco R; Rodríguez-Valverde V; Martínez-Taboada VM; Delgado-Rodriguez M; Figueroa M; Uriarte E
Arthritis Rheum; 1998 Aug; 41(8):1497-504. PubMed ID: 9704651
[TBL] [Abstract][Full Text] [Related]
8. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity.
Weyand CM; Fulbright JW; Hunder GG; Evans JM; Goronzy JJ
Arthritis Rheum; 2000 May; 43(5):1041-8. PubMed ID: 10817557
[TBL] [Abstract][Full Text] [Related]
9. [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose].
Chevalet P; Barrier JH; Glémarec J; el Kouri D; Hamidou M; de Wazières B; Duhamel E; Jégo P; Maugars Y; Planchon B; Rodat O
Rev Med Interne; 2001 Jul; 22(7):624-30. PubMed ID: 11508155
[TBL] [Abstract][Full Text] [Related]
10. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
Nesher G; Berkun Y; Mates M; Baras M; Rubinow A; Sonnenblick M
Arthritis Rheum; 2004 Apr; 50(4):1332-7. PubMed ID: 15077317
[TBL] [Abstract][Full Text] [Related]
11. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
Hernández-Rodríguez J; Segarra M; Vilardell C; Sánchez M; García-Martínez A; Esteban MJ; Queralt C; Grau JM; Urbano-Márquez A; Palacín A; Colomer D; Cid MC
Rheumatology (Oxford); 2004 Mar; 43(3):294-301. PubMed ID: 14679293
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of visual outcome after visual loss from giant cell arteritis.
Danesh-Meyer H; Savino PJ; Gamble GG
Ophthalmology; 2005 Jun; 112(6):1098-103. PubMed ID: 15885780
[TBL] [Abstract][Full Text] [Related]
14. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up.
Bresci G; Parisi G; Mazzoni A; Scatena F; Capria A
J Gastroenterol Hepatol; 2008 Nov; 23(11):1678-82. PubMed ID: 18823440
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
Brauer VF; Scholz GH
Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
[TBL] [Abstract][Full Text] [Related]
17. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
[TBL] [Abstract][Full Text] [Related]
18. [Complications during systemic corticosteroid therapy combined with orbital radiotherapy in patients with graves orbitopathy].
Kulig G; Kaźmierczyk-Puchalska A; Krzyzanowska-Swiniarska B; Pilarska K
Przegl Lek; 2004; 61(8):855-6. PubMed ID: 15789916
[TBL] [Abstract][Full Text] [Related]
19. [Principles of acute treatment of Horton's disease. Role of high-dose corticosteroid therapy].
Barrier JH; Chevalet P; Ponge T
Ann Med Interne (Paris); 1998 Nov; 149(7):448-53. PubMed ID: 9921399
[TBL] [Abstract][Full Text] [Related]
20. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality.
González-Gay MA; Blanco R; Abraira V; García-Porrúa C; Ibáñez D; García-Pais MJ; Rigueiro MT; Sánchez-Andrade A; Guerrero J; Casariego E
J Rheumatol; 1997 Nov; 24(11):2171-6. PubMed ID: 9375880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
